Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

Safe Biologics

JUNE 12, 2023

Op-ed: IRA Drug Price Controls Will Hurt Cancer Drug Development On May 18th, an op-ed by ASBM Steering Committee Member Andrew Spiegel ran in the Reading Eagle. Unfortunately, the new drug-pricing rules enacted in the Inflation Reduction Act will stymie efforts to develop new cancer treatments.

Drug Pricing 100

Drug Pricing Drug Development Compounding 100

STAT

JUNE 20, 2024

We have adjusted our settings to accept postcards and telegrams… After taking legal action last year, Eli Lilly filed even more lawsuits against several spas, compounders and wellness centers over unapproved versions of tirzepatide, which is the active ingredient in Mounjaro and Zepbound,   STAT notes.

Diabetes 277

Diabetes Compounding Drug Pricing Drug Development 277

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. This obviously presents a huge magnitude of risk for drug developers,” he noted.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

pharmaphorum

AUGUST 27, 2020

Regulatory pressures, lengthy drug development times, and the fact that drug prices have become politicised have raised risks and cut revenue projections, leading to the biotech sector falling out of fashion.

Vaccines 122

Vaccines Drug Pricing Compounding Immunity 122